Home > Neurology > EAN 2022 > Multiple Sclerosis > Ofatumumab improves cognitive processing speed

Ofatumumab improves cognitive processing speed

Presented By
Prof. Ralph H.B. Benedict, University at Buffalo, NY, USA
Conference
EAN 2022
Trial
Phase 3, ASCLEPIOS I/II
Doi
https://doi.org/10.55788/aef6bd45
In the phase 3 ASCLEPIOS I/II trials, ofatumumab was associated with more clinically meaningful improvements in cognitive processing speed (CPS) compared with teriflunomide, as measured by changes in Symbol Digit Modalities Test (SDMT) scores. This was observed in the overall population and in the subgroup of patients recently diagnosed with multiple sclerosis (MS). Cognitive impairment presents in 40–70% of MS patients, can start early in the disease course, and can have a profoundly negative effects on quality-of-life. Cognitive impairment, particularly CPS, also seems to be able to predict MS progression. In trials, CPS is often measured with the SDMT. Early baseline screening with the SMDT or a similar validated test is recommended for clinically stable patients. The phase 3 ASCLEPIOS I and II trials (NCT02792231,


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on